Urologix, Inc. announced unaudited earnings results for the first quarter ended September 30, 2013. For the period, the company reported sales of $3,779,000, operating loss of $1,162,000, loss before income taxes of $1,322,000 and net loss of $1,334,000 or $0.06 per diluted share compared to sales of $3,970,000, operating loss of $926,000, loss before income taxes of $1,053,000 and net loss of $1,069,000 or $0.05 per diluted share a year ago period. Net cash used for operating activities was $734,000 against $414,000 a year ago period. Purchase of property and equipment was $2,000 against $4,000 a year ago period. Results in the first quarter of fiscal year 2014 were negatively impacted by a significant slowdown in international sales of Prostiva. First quarter revenue declined 9.7% sequentially driven primarily by a decline in sales of disposable products from both product lines.

The company is reaffirming the fiscal year 2014 total revenue guidance range of $15 million to $17 million.